TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3704666

Group type: EXPERIMENTAL
Intervention: Phlebotomy alone
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 32P
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (phlebotomy)
Number of subjects: 432
Study: 31972249

Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg (n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg (n = 7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PF-06700841 (both dosages)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 30
Study: 30907230

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27390168

Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atacicept exposure (quartiles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of BLyS and APRIL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infection rates
Number of subjects: 0
Study: 25850386

Group type: EXPERIMENTAL
Intervention: Printed educational material
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Academic detailing to primary care physicians
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Academic detailing plus tailored telephone education
Number of subjects: 564
Study: 23391760

Group type: EXPERIMENTAL
Intervention: MWM‐with‐Tape
Number of subjects: 25

Group type: COMPARATOR
Intervention: MWM
Number of subjects: 25
Study: 21410557

Group type: EXPERIMENTAL
Intervention: Conventional restorative treatment
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Ultraconservative treatment
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (children receiving local anaesthesia)
Number of subjects: 244
Study: 19597879

Group type: EXPERIMENTAL
Intervention: Heparin responsiveness in stabilized IE patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (48 patients without systemic infection)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Preoperative antithrombin III activity
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Preoperative fibrinogen level
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heparin resistance
Number of subjects: 16
Study: 18057479

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15041603

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 68

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 68
Study: 11339485

Group type: EXPERIMENTAL
Intervention: Fat Free Mass (FFM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Total Body Mass (TBM)
Number of subjects: 10
Study: 9218071

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg nocte
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8432920

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (Philips TL 01)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (Philips TL 01) with dithranol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional broad-band UVB (Sylvania UV 6)
Number of subjects: 23
Study: 2979684

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (average dose 10 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intravenous diazepam in lipid emulsion (average dose 18.4 mg)
Number of subjects: 101
Study: 30759357

Group type: EXPERIMENTAL
Intervention: Impairment-based manual therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham manual therapy (control)
Number of subjects: 72
Study: 28281738

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg daily from 30 min before and up to 3 days after procedure)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (intravenous hydration only)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 128
Study: 26674626

Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a combined with ribavirin for 48 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a combined with ribavirin for 72 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Previously treated with interferon alone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Previously treated with interferon plus ribavirin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Previously treated with common interferon (c‐IFN)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Previously treated with Peg‐IFN
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rapid virological response (RVR)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Complete early virological response
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RVR, early virological response, delayed virological response
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 125
Study: 23483064

Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium 2 g/12 h and intravenous human albumin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 100
Study: 20974077

Group type: EXPERIMENTAL
Intervention: Online health intervention
Number of subjects: 0
Study: 18981044

Group type: EXPERIMENTAL
Intervention: Inhaled L-methamphetamine (16 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled L-methamphetamine (48 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16684019

Group type: EXPERIMENTAL
Intervention: CRT-D device
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: History of spontaneous, sustained ventricular arrhythmia
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: NYHA class IV CHF
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: NYHA class II CHF excluded from analysis
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: CRT-D device in patients with NYHA class IV CHF
Number of subjects: 501
Study: 12716688

Group type: EXPERIMENTAL
Intervention: Folic acid 50, 100, 200, 400, 600, or 800 micro g daily for 12 weeks
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Folic acid (estimated adequate dose) 392 micro g daily
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 10939175

Group type: EXPERIMENTAL
Intervention: Comprehensive Coping Strategy Program (CCSP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 8636540

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy with transient ischemia (group I)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Beta-blocker therapy without transient ischemia (group II)
Number of subjects: 313
Study: 1592646

Group type: EXPERIMENTAL
Intervention: Peridural analgesia (PDA) with bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous analgesia (IVA) with pentazocine
Number of subjects: 48
Study: 3913095

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30789785

Group type: EXPERIMENTAL
Intervention: Providing detailed process information about conflict resolution in withholding treatment (second opinion, ethics consultation, exploring transfer to another institution)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1191
Study: 30198057

Group type: EXPERIMENTAL
Intervention: Resminostat plus sorafenib (resminostat 400 mg/day on days 1 to 5 every 14 days, sorafenib 800 mg/day for 14 days)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Sorafenib monotherapy (800 mg/day)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Combination therapy (resminostat plus sorafenib)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Sorafenib monotherapy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Combination therapy (resminostat plus sorafenib) among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Sorafenib monotherapy among patients with normal-to-high baseline platelet count (≥ 150 × 103/mm3)
Number of subjects: 179
Study: 27521970

Group type: EXPERIMENTAL
Intervention: Oxycodone and dexmedetomidine (group OD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oxycodone alone (group O)
Number of subjects: 84
Study: 25561816

Group type: EXPERIMENTAL
Intervention: Gemcitabine and S‐1 combination therapy (recurrent group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine and S‐1 combination therapy (unresectable group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine (recurrent group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine (unresectable group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐1 (recurrent group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐1 (unresectable group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenia (recurrent group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenia (unresectable group)
Number of subjects: 0
Study: 22634189

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whey protein and Maltodextrin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maltodextrin and Whey protein
Number of subjects: 19
Study: 20215710

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, 70 mg/dL for secondary prevention)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007)
Number of subjects: 400
Study: 19469273

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (2 mg of estradiol and 0.5 mg of norgestrel)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cimicifuga recemosa (refemin)
Number of subjects: 94
Study: 15916866

Group type: EXPERIMENTAL
Intervention: L-methadone
Number of subjects: 75

Group type: COMPARATOR
Intervention: D,L-methadone
Number of subjects: 75
Study: 12428068

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate plus metronidazole and amoxicillin (group A)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Ranitidine and metoclopramide (group B)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Eradication therapy after 3 months for group B non-responders
Number of subjects: 157

Group type: COMPARATOR
Intervention: Non-eradicated cases (group B)
Number of subjects: 157
Study: 10891819

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth-restricted children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-growth-restricted children
Number of subjects: 0
Study: 8880666

Group type: EXPERIMENTAL
Intervention: strengths‐based case management
Number of subjects: 632

Group type: COMPARATOR
Intervention: substance abuse treatment without case management
Number of subjects: 632
Study: 1319109

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: n-3 ethyl esters
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 12

Group type: COMPARATOR
Intervention: All three diets
Number of subjects: 12
Study: 6742383

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90
Study: 31525580

Group type: EXPERIMENTAL
Intervention: Interruptive clinical decision support (CDS) alerts
Number of subjects: 958

Group type: COMPARATOR
Intervention: Non-interruptive clinical decision support (CDS) alerts
Number of subjects: 958
Study: 29377735

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 300
Study: 26898340

Group type: EXPERIMENTAL
Intervention: Gentamicin impregnated collagen sponge (GICS) at gentamicin dose = 6 mg/kg (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham operation (n = 9)
Number of subjects: 18
Study: 23893101

Group type: EXPERIMENTAL
Intervention: Immediate treatment (PEERS intervention)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist comparison group
Number of subjects: 58
Study: 21803927

Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements at more than four places
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Exposure to tobacco advertisements at more than four places among boys
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: High receptivity to tobacco advertising among boys
Number of subjects: 2782

Group type: COMPARATOR
Intervention: Control group (non-exposed to tobacco advertisements)
Number of subjects: 2782
Study: 21146673

Group type: EXPERIMENTAL
Intervention: FTO risk allele (A)
Number of subjects: 21674

Group type: EXPERIMENTAL
Intervention: Less-active women (≤8.8 metabolic equivalent‐h/wk) with FTO risk allele (A/A)
Number of subjects: 21674

Group type: COMPARATOR
Intervention: More-active women
Number of subjects: 21674
Study: 17924889

Group type: EXPERIMENTAL
Intervention: Continuous remifentanil infusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fentanyl bolus administration
Number of subjects: 46
Study: 15784108

Group type: EXPERIMENTAL
Intervention: Increase in daytime symptoms of 1-5 U over baseline
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Increase in daytime symptoms of two or more over baseline
Number of subjects: 983
Study: 11095542

Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP) program delivered via bibliotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study: 9024516

Group type: EXPERIMENTAL
Intervention: Heparin solution (25 U/ml) with vancomycin (25 mcg/ml) for daily catheter flush (HepVan)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Heparin solution (25 U/ml) without vancomycin (Hep)
Number of subjects: 83
Study: 8333266

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3101502

Group type: EXPERIMENTAL
Intervention: Viscoelastic tear formulations (including hyaluronic acid and chondroitin sulfate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyvinyl alcohol artificial tear
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyvinyl alcohol or hyaluronic acid solution
Number of subjects: 20
Study: 2634104

Group type: EXPERIMENTAL
Intervention: 15-session smoking prevention intervention
Number of subjects: 471
Study: 31199766

Group type: EXPERIMENTAL
Intervention: Dysentery compound (DC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individualized homeopathy (IH)
Number of subjects: 60
Study: 28388661

Group type: EXPERIMENTAL
Intervention: Higher community involvement (volunteer activities, community events, clubs for the elderly)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Higher community involvement (for older women living with others)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Individual relationship (friendship, communication with family and friends, hobbies)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Overall psychological distress
Number of subjects: 825
Study: 25633208

Group type: EXPERIMENTAL
Intervention: Small change eating and physical activity intervention (SC) combined with positive affect and self-affirmation (PA/SA) intervention
Number of subjects: 574

Group type: COMPARATOR
Intervention: Small change eating and physical activity intervention (SC) alone
Number of subjects: 574
Study: 22828963

Group type: EXPERIMENTAL
Intervention: Structured supervised group exercises, group lectures, individual counselling and telephone follow‐up
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 21257787

Group type: EXPERIMENTAL
Intervention: Filtered air (using portable air filters)
Number of subjects: 45
Study: 19193426

Group type: EXPERIMENTAL
Intervention: Ileocolonic neobladder
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ileal neobladder
Number of subjects: 71
Study: 16389165

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (5 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (7.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study: 15194383

Group type: EXPERIMENTAL
Intervention: Somatostatin administration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no somatostatin)
Number of subjects: 21
Study: 12774336

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both LNF and ONF
Number of subjects: 42
Study: 9059166

Group type: EXPERIMENTAL
Intervention: Preci-Jet 50 transjector for growth hormone delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pen injection system for growth hormone delivery
Number of subjects: 0
Study: 8377957

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate, 15 mg weekly
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2439800

Group type: EXPERIMENTAL
Intervention: Bisoprolol (20 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg)
Number of subjects: 5
Study: 28693638

Group type: EXPERIMENTAL
Intervention: Referral to a community counselling service (quitline, text-based program, web-based program)
Number of subjects: 1295

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1295
Study: 27524403

Group type: EXPERIMENTAL
Intervention: Individual pain treatment for eight weeks
Number of subjects: 352

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 352
Study: 24554388

Group type: EXPERIMENTAL
Intervention: Higher dose of 50‐60 min of aerobic exercise (HIGH; n = 101)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combined dose of 50‐60 min of aerobic and resistance exercise (COMB; n = 104)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard dose of 25‐30 min of aerobic exercise (STAN; n = 96)
Number of subjects: 301
Study: 23301468

Group type: EXPERIMENTAL
Intervention: Acupuncture + medication (electroacupuncture at Baihui, Yintang, Sishencong, Taichong, Sanyinjiao) with oral administration of madopar and fluoxetine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (oral administration of madopar and fluoxetine)
Number of subjects: 60
Study: 20522567

Group type: EXPERIMENTAL
Intervention: Injection of lidocaine and bupivacaine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group from INVEST trial
Number of subjects: 19
Study: 18430433

Group type: EXPERIMENTAL
Intervention: Counterexample retrieval in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional reasoning task in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modus ponens inference in Experiment 2
Number of subjects: 0
Study: 16544441

Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12967798

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with intraoperative perfluoro-n-octane (PFO)
Number of subjects: 555
Study: 11075315

Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9163278

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketamine racemate 2 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 0.5 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketamine racemate 1 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 2 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketamine racemate 4 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg with midazolam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ketamine racemate 2 mg/kg with midazolam
Number of subjects: 54
Study: 8369784

Group type: EXPERIMENTAL
Intervention: Fixed-triple combination of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Individual administration of isoniazid (750 mg), rifampicin (600 mg), and pyrazinamide (2,250 mg)
Number of subjects: 6
Study: 3526102

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 16
Study: 31063574

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg (n=1208)
Number of subjects: 2422

Group type: COMPARATOR
Intervention: Placebo (n=1214)
Number of subjects: 2422
Study: 28750737

Group type: EXPERIMENTAL
Intervention: 10 ppm NO inhalation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26837983

Group type: EXPERIMENTAL
Intervention: 1% phenytoin mouthwash
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study: 23530474

Group type: EXPERIMENTAL
Intervention: PCI followed by Postconditioning (PostC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 68
Study: 21470289

Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia (Group 2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: General anaesthesia (Group 1)
Number of subjects: 25